Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2023 16:10 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces Second Quarter 2023 Financial Results

– Continued progress in clinical development across portfolio –– Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif., Aug. 03, 2023 ...
July 03, 2023 16:01 ET | Source: IGM Biosciences, Inc.

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

MOUNTAIN VIEW, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its previously announced upsized underwritten public offering of...
June 22, 2023 07:58 ET | Source: IGM Biosciences, Inc.

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

MOUNTAIN VIEW, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its...
June 21, 2023 17:17 ET | Source: IGM Biosciences, Inc.

IGM Announces Proposed Public Offering and Concurrent Private Placement

MOUNTAIN VIEW, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common...
June 02, 2023 17:30 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients – – Progression-free survival of 5.6 months...
June 01, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at the Jefferies Healthcare Conference

MOUNTAIN VIEW, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
May 31, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

MOUNTAIN VIEW, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
May 30, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update

– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology...
May 12, 2023 09:05 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update

– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of...
May 02, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...